...Ying Wang; Long Jiang; Shu-Jun Feng; Xin-Ying Tang; Ze-Min Kuang Introduction: This meta-analysis aimed to explore the preventive effects of combined statin and antihypertensive therapy on major cardiovascular outcomes in patients with hypertension. Methods: PubMed, Embase, and the Cochrane Library...

...Jean Ferrières; Vian Amber; Oliviu Crisan; François Chazelle; Claus Jünger; David Wood Objectives: Despite statin use, many patients with cardiovascular disease (CVD) are not achieving treatment goals. An international observational study was performed to estimate the prevalence of residual lipid...

...Luis Afonso; Vikas Veeranna; Sandip Zalawadiya; Krithi Ramesh; Ashutosh Niraj; Sidakpal Panaich Background: Low-density lipoprotein cholesterol-lowering therapy is an important aspect of primary prevention of cardiovascular disease (CVD). Statins are the most widely used drug therapy for achieving...

...P. Brudi; J.P. Reckless; D.P. Henry; T. Pomykaj; S.T. Lim; R. Massaad; K. Vandormael; A.O. Johnson-Levonas Objective: The aim of the study was to compare the efficacy/safety of doubling the dose of low-, medium- and high-potency statins on lipids/lipoproteins versus ezetimibe/simvastatin (EZE/SIMVA...

... studies showed the possible role of endothelial dysfunction, diffuse atherosclerosis and inflammation in the pathogenesis of this phenomenon. We aimed to investigate the effect of statin on myocardial perfusion in patients with SCF. Methods and Results: The study population consisted of 97 patients...

...Renato Razzolini; Giuseppe Tarantini; Giovanni Ossena; Enrico Favaretto; Claudio Bilato; Enzo Manzato; Sergio Dalla-Volta; Sabino Iliceto Background: As of today, the effect of statins on non-cardiovascular mortality is still being debated. Single studies have not been able to provide definite...

... in either CAD group (p = 0.82), or the control group (p = 0.85). In a subgroup of 13 patients who were not under statin treatment, we found a strong correlation between the levels of these molecules (p = 0.01). Conclusion: Our study does not clearly support or exclude a link between CRP and ET-1 in patients...

...Henry Krum; Michael Bailey; Wilfried Meyer; Patricia Verkenne; Henry Dargie; Phillipe Lechat; Stefan Anker Background: HMG-CoA reductase inhibitors (statins) are widely prescribed in patients with established systolic chronic heart failure (CHF). However, there is considerable controversy regarding...

...Kun-Tai Lee; Wen-Ter Lai; Chin-Sheng Chu; Li-Yu Tsai; Hsueh-Wei Yen; Wen-Choi Voon; Sheng-Hsiung Sheu Background: C-reactive protein is considered a risk factor for coronary artery disease. In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein. Abrupt...

...Herbert Schuster Rosuvastatin (Crestor ® ; licensed to AstraZeneca, Macclesfield, UK from Shionogi, Osaka, Japan) is a new statin with pharmacologic characteristics that translate into selectivity of effect in hepatic cells and enhanced potency in 3-hydroxy-3-methylglutaryl coenzyme A reductase...

... community. The 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors (statins) are the most widely prescribed and best tolerated of the currently available lipid-modifying therapies. Newer agents in this class (e.g. rosuvastatin) have been developed that have proven to be more...

...J. Bradley Oldemeyer; Richard J. Lund; Matt Koch; A. John Meares; Robert Dunlay Statin-fibrate combinations are commonly used to treat hyperlipidemia. These drugs have been previously reported to cause rhabdomyolysis with acute renal failure. Whether different statin-fibrate combinations have...